Daniel G. Baker - 25 Nov 2024 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ Daniel G. Baker by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
25 Nov 2024
Net transactions value
$0
Form type
4
Filing time
29 Nov 2024, 16:00:05 UTC
Next filing
29 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 25 Nov 2024 Common Stock 200,000 $1.06 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an inducement stock option granted on November 25, 2024.
F2 This stock option will become exercisable over two years in equal, semi-annual installments beginning on May 25, 2025.